Stephen Dechter, DO
Pain Medicine · Pasco, WANPI 1568635365
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $5,399 of the $7,178 with a category attached, or 75.2%. Nevro Corp. accounts for 68.2% of it on its own, with 21 other manufacturers making up the rest. Reporting peaked in 2019 at $3,810 and has fallen 94.9% since, to $195 in 2025.
Across 195 payments — averaging $36.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Nevro Corp.$5K
- Boston Scientific$757
- Stryker$276
- Nalu Medical, Inc.$234
- Zyla Life Sciences, Inc.$166
- Supernus Pharmaceuticals, Inc.$147
- plus $702 from 16 others
What the payments were for
- Travel & lodging$1,77925%
- Food & beverage$5,39975%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Nevro Corp. | 104 | $4,897 |
| Boston Scientific | 26 | $757 |
| Stryker | 2 | $276 |
| Nalu Medical, Inc. | 3 | $234 |
| Zyla Life Sciences, Inc. | 12 | $166 |
| Supernus Pharmaceuticals, Inc. | 20 | $147 |
| Medtronic(2 entities) | 4 | $145 |
| Relievant Medsystems, Inc. | 1 | $85 |
| Daiichi Sankyo Inc. | 3 | $68 |
| MDD US Operations, LLC | 4 | $52 |
| Biotronik NRO, Inc. | 2 | $52 |
| Pfizer | 2 | $47 |
| Globus Medical | 1 | $40 |
| Curonix LLC | 1 | $37 |
| Lilly USA, LLC | 2 | $30 |
| Fidia Pharma USA Inc. | 1 | $30 |
| AbbVie | 1 | $24 |
| Collegium Pharmaceutical, Inc. | 2 | $22 |
| Saluda Medical Americas, Inc. | 1 | $22 |
| Abbott | 1 | $21 |
| Teva Pharmaceuticals USA, Inc. | 1 | $16 |
| Novartis | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,178 in reported general payments places this provider in the 75th percentile of 124 pain medicine providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Xtampza ErOxycodone Myristate | 13 | $28,767 |
| Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen | 85 | $2,430 |
| Hydrocodone-AcetaminophenHydrocodone/Acetaminophen | 87 | $1,594 |
| Oxycodone Hcl | 62 | $1,233 |
| Gabapentin | 94 | $1,085 |
| Pregabalin | 33 | $395 |
| Baclofen | 42 | $386 |
| Tizanidine Hcl | 27 | $263 |
| Cyclobenzaprine Hcl | 36 | $138 |
| Methylprednisolone | 19 | $132 |
| Celecoxib | 13 | $121 |
| Tramadol Hcl | 21 | $42 |
| Meloxicam | 23 | $38 |
| Diazepam | 21 | $27 |
| Fluconazole | 11 | $15 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Collegium Pharmaceutical, Inc.Xtampza Er | $22 | $28,76713 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 124 pain medicine providers in Washington.
Other pain medicine in Pasco
- Jennifer LeeKirkland$318K
- Steven StanosSeattle$206K
- Corrie AndersonSeattle$102K
- Gregory TermanSeattle$95K
- Caroline HarstroemEverett$74K
- Sloane YuVancouver$42K
- Praveen MambalamEdmonds$32K
- Miroslav BackonjaSeattle$22K
- Ross VogelgesangOlympia$21K
- Jon HillyerSilverdale$20K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.